// App-Quantinova.ai

: Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)

Researchers

Presenter

  • Wentao Chen

Principal Investigators

  • Clare Hardman

  • Paul Batty

  • Jian Luo

  • Yanqiu Wu

  • Luzheng Xue

  • Graham Ogg

  • David A Sandham

  • Veit J Erpenbeck

Medical Centers

  • Respiratory Medicine Unit and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  • Medical Research Council Human Immunology Unit, University of Oxford, Oxford, United Kingdom,

  • Novartis Institute for Biomedical Research, Cambridge, MA, United States

  • Novartis AG, Basel, Switzerland

Locations

  • United Kingdom

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Prostaglandin D2

Drug/Treatment

  • Prostaglandin

  • Fevipiprant

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved